Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Aug;45(8):e70208.
doi: 10.1111/liv.70208.

Association of Plasma Lipoprotein(a) With Major Adverse Cardiovascular Events in MASLD With or Without Advanced Liver Fibrosis

Tie Xiao  1 , Hui-Hui Liu  2 , Na Tian  1 , Li-You Lian  1 , Kai-Wen Miao  1 , Yu-Ting Li  1 , Li-Li Chen  1 , Hai-Yang Yuan  1 , Mulong Du  3 , Shanshan Wu  4 , Feng Sun  5 , Giovanni Targher  6   7 , Christopher D Byrne  8 , Michael D Shapiro  9 , Gregory Y H Lip  10   11 , Xiao-Dong Zhou  1 , Jian-Jun Li  2 , Ming-Hua Zheng  1   12   13 ; WMU MAFLD Clinical Research Working Group
Collaborators, Affiliations
Multicenter Study

Association of Plasma Lipoprotein(a) With Major Adverse Cardiovascular Events in MASLD With or Without Advanced Liver Fibrosis

Tie Xiao et al. Liver Int. 2025 Aug.

Abstract

Background and aims: There is uncertainty regarding the role of plasma lipoprotein(a) [Lp(a)] in predicting cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). We examined the association between plasma Lp(a) concentrations and major adverse cardiovascular events (MACE) in MASLD, stratified by the severity of liver fibrosis.

Methods: This study enrolled patients with MASLD from two centres. Lp(a) percentile groups were generated with the reference group set at the 1st-50th Lp(a) percentiles. High Lp(a) levels correspond to the 91st-100th percentile. Advanced liver fibrosis was defined using the fibrosis (FIB)-4 index > 2.67. MACE was defined as myocardial infarction, ischemic stroke, or cardiovascular death. Cox regression was used to assess the association between the Lp(a) percentile groups and MACE.

Results: A total of 56 168 patients with MASLD were followed for a median of 5.0 years (IQR: 2.0-8.5 years), and 6136 patients developed incident MACE. There was an inverse association between Lp(a) percentiles and advanced liver fibrosis (91st-100th percentile, adjusted OR = 0.65, 95% CI 0.59-0.72; p < 0.001). In patients with advanced liver fibrosis, there was a lower proportion in the high Lp(a) levels group (p < 0.001), although the incidence of MACE remained high. MASLD patients with advanced liver fibrosis and high Lp(a) levels had a higher risk of MACE (adjusted HR = 1.56, 95% CI 1.27-1.91; p < 0.001) than those with low Lp(a) levels.

Conclusions: Plasma Lp(a) levels are lower in MASLD patients with advanced fibrosis, yet their MACE risk remains high, suggesting that relying on Lp(a) alone may underestimate cardiovascular risk if advanced liver fibrosis is not considered.

Keywords: cardiovascular disease; lipoprotein(a); liver fibrosis; metabolic dysfunction‐associated steatotic liver disease.

PubMed Disclaimer

References

    1. M. Ruscica, C. R. Sirtori, A. Corsini, G. F. Watts, and A. Sahebkar, “Lipoprotein(a): Knowns, Unknowns and Uncertainties,” Pharmacological Research 173 (2021): 105812, https://doi.org/10.1016/j.phrs.2021.105812.
    1. B. G. Nordestgaard and A. Langsted, “Lipoprotein(a) and Cardiovascular Disease,” Lancet 404, no. 10459 (2024): 1255–1264, https://doi.org/10.1016/S0140‐6736(24)01308‐4.
    1. S. Mora and F. Kronenberg, “Lipoprotein(a),” JAMA 333 (2025): 1918–1919, https://doi.org/10.1001/jama.2025.2373.
    1. F. Kronenberg, S. Mora, E. S. G. Stroes, et al., “Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement,” European Heart Journal 43, no. 39 (2022): 3925–3946, https://doi.org/10.1093/eurheartj/ehac361.
    1. S. Tsimikas, “A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies,” Journal of the American College of Cardiology 69, no. 6 (2017): 692–711, https://doi.org/10.1016/j.jacc.2016.11.042.

Publication types

LinkOut - more resources